NEWS
Biomerica Secures Three Key International Patents for inFoods® Technology to Address GERD, Crohn’s Disease, and Ulcerative Colitis
Biomerica (NASDAQ: BMRA) has secured three key patent allowances in European markets for its inFoods® Technology, targeting GERD, Crohn's Disease, and Ulcerative Colitis. The patents cover major European markets including Germany, UK, France, Italy, Spain, and over 30 other EPO nations. These markets represent significant opportunities: GERD ($4B+ annually), Crohn's Disease ($2.5B+ annually), and Ulcerative Colitis (projected $1.9B by 2028). The inFoods® Technology platform identifies specific foods triggering symptoms in patients, enabling personalized dietary plans as alternatives to traditional medications, particularly addressing concerns over PPI side effects in GERD treatment.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment